GCM
DNA icon

Glenview Capital Management’s Ginkgo Bioworks DNA Stock Holding History

Glenview Capital Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-149,379
Closed -$1.24M – 51
2025
Q4 		$1.24M Hold
149,379
– – 0.03% 56
2025
Q3 		$2.18M Hold
149,379
– – 0.05% 53
2025
Q2 		$1.68M Sell
149,379
-38,122
-20% -$295K 0.05% 41
2025
Q1 		$1.07M Hold
187,501
– – 0.03% 44
2024
Q4 		$1.84M Sell
187,501
-287,497
-61% -$2.46M 0.05% 34
2024
Q3 		$3.87M Sell
474,998
-187,502
-28% -$1.88M 0.08% 41
2024
Q2 		$8.86M Buy
662,500
+62,500
+10% +$1.86M 0.19% 43
2024
Q1 		$27.8M Buy
+600,000
New +$31.1M 0.54% 32

Other funds holding DNA

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.18B AUM 27.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return